Amyloid Monoclonal Antibody Treatment in PD Patients With Coexistent AD Pathology

NCT07544953 · clinicaltrials.gov ↗

NA

Phase

NOT_YET_RECRUITING

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Parkinson Disease

Interventions

DRUG: Lecanemab
OTHER: Lecanemab non-administration group

Sponsor

Yonsei University